IMMIX BIOPHARMA INC. - COMMON STOCK
2.4700
17-May-24 14:59:51
15 minutes delayed
Stocks
+0.2200
+9.78%
Today's range
2.2500 - 2.4746
ISIN
N/A
Source
NASDAQ
-
10 May 2024 08:35:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
29 Apr 2024 08:39:00 By Nasdaq GlobeNewswire
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 Apr 2024 08:32:00 By Nasdaq GlobeNewswire
-
20 Mar 2024 08:46:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
05 Mar 2024 08:35:00 By Nasdaq GlobeNewswire
-
Immix Biopharma 12 Month Review Progress Update
21 Feb 2024 08:31:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 Feb 2024 15:45:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
07 Feb 2024 08:37:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 Feb 2024 21:30:00 By Nasdaq GlobeNewswire
-
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 Feb 2024 14:20:11 By Nasdaq GlobeNewswire
-
24 Jan 2024 07:35:00 By Nasdaq GlobeNewswire
-
18 Dec 2023 08:39:00 By Nasdaq GlobeNewswire
-
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
30 Nov 2023 08:46:00 By Nasdaq GlobeNewswire
-
22 Nov 2023 08:19:00 By Nasdaq GlobeNewswire
-
21 Nov 2023 08:46:00 By Nasdaq GlobeNewswire
-
21 Nov 2023 08:46:00 By Nasdaq GlobeNewswire
-
06 Nov 2023 08:12:00 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >